Azamian Bobak R. sold $803K of TARS (indirect holdings)

Azamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at $80.31 ($0.80M total) on 2026-11-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Azamian Bobak R.
Published Nov 18, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TARS
Neutral
medium confidence
Mentioned
$TARS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TARSNeutralLow
01

Why it matters

The disclosure provides transparency on CEO/Chair selling activity, but it does not include new company performance, guidance, or regulatory/clinical milestones.

02

Market read

This is a routine insider-sale filing with modest sentiment relevance, not a fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent news catalysts (earnings, trial results, financing) which are not present in this filing excerpt.

Relevance 4/10Novelty 5/10Timing: filed 2026-11-17, transaction dated 2026-11-13

Background

The article is an SEC Form 4 insider transaction disclosure for Tarsus Pharmaceuticals, Inc.

Company-level read

Ticker impact

$TARSNeutralMedium confidence
Context

SEC Form 4 shows Tarsus Pharmaceuticals CEO/Chair Azamian Bobak R. sold 10,000 shares at $80.31 on a 10b5-1 plan.

Expected impact

Likely limited, with any downside pressure fading as the market treats the sale as routine 10b5-1 execution.

Evidence & confidence

The filing is a primary SEC Form 4 disclosure, but the transaction is explicitly under a pre-arranged 10b5-1 plan and is not accompanied by new operational or guidance information.

Market effects

Minimal, as this is a single-company insider sale with no stated sector-wide regulatory or clinical update.

None.

None.

Counterpoint

Because the sale is on a 10b5-1 plan, it may reflect scheduled liquidity needs rather than any change in fundamentals, so price impact may be negligible.

Key entities

  • Tarsus Pharmaceuticals, Inc.

    US-listed company whose CEO/Chair executed a 10b5-1 open-market sale disclosed on Form 4.

  • Azamian Bobak R.

    President/CEO and Board Chair who sold 10,000 shares indirectly under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TARSHighAI 8/10

Tarsus (TARS) Q3 2026 Earnings Call Transcript

Tarsus (TARS) reported Q3 2026 net product sales of $194.6M for XDEMVY, up 64% YoY. The company raised full-year sales guidance to $715M-$730M. Key growth drivers include increased patient demand, broader ECP prescribing, and retreatment. Tarsus also discussed pipeline progress and acquisition integration.

$TARSMedAI 8/10

Tarsus Pharmaceuticals Q3 Earnings Call Highlights

Tarsus Pharmaceuticals (NASDAQ:TARS) increased its 2026 XDEMVY sales outlook to $715M-$730M, citing stronger demand and advertising returns. Q3 saw 20% sequential growth in high-prescribing eye care professionals. The company expects 2027 direct-to-consumer spending of $80M-$95M. Gross margin is projected at 93%, with SG&A and R&D expenses outlined. Pipeline updates include TP-03 launch in China and upcoming trials for TP-04, TP-05, and IRX-101.